Graft-versus-host disease
|
Graft-versus-host disease |
|
Differentiating Graft-versus-host disease from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Graft-versus-host disease On the Web |
|
American Roentgen Ray Society Images of Graft-versus-host disease |
|
Risk calculators and risk factors for Graft-versus-host disease |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Shyam Patel [2]
Synonyms and keywords: GVHD
Overview
Graft-versus-host disease (GvHD) is a condition characterized by recipient tissue damage that arise from immunological activation of donor T lymphocytes. It typically occurs in the setting of bone marrow transplantation. Donor T cells mount a response against foreign host cells in the gastrointestinal system, liver, and skin.
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Graft-versus-host disease from Other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms | Physical Examination | Laboratory Findings | Chest X Ray | CT | Other Imaging Findings | Other Diagnostic Studies
Treatment
The treatment of GvHD focuses on immunosuppression. Immunosuppression is usually achieved by administering steroids, auch as prednisone or methylprednisolone. Alternative agents include immunophilins like cyclosporine or tacrolimus. Ruxolitinib has been used for GvHD that is refractory to steroids.
| Primary Prevention | Secondary Prevention | Cost-Effectiveness of Therapy | Future or Investigational Therapies